McMillan T J, Stephens T C, Peacock J H, Steel G G
Radiotherapy Research Unit, Institute of Cancer Research, Sutton, Surrey, U.K.
Eur J Cancer Clin Oncol. 1987 Jun;23(6):801-5. doi: 10.1016/0277-5379(87)90282-3.
The development of resistance to MeCCNU in four clonal lines of Lewis lung carcinoma derived from lung colonies has been examined. Treatment of the clones with 15 mg/kg MeCCNU once in each in vivo passage resulted in a rapid reduction in tumour responsiveness to this drug. This shows that MeCCNU resistance can arise at rates which may be applicable in spontaneous tumours and their metastases. Karyotypic heterogeneity was evident very early after isolation of the clones and this has potentially important implications for the experimental use of clones and for the features of metastatic disease. Karyotype analysis of one of the clones at each passage suggested that development of resistance was associated with the selection of a single sub-population of tumour cells but the kinetics of resistance development cannot be totally explained in terms of this simple selection.
对源自肺集落的四株Lewis肺癌克隆系中甲基环己亚硝脲(MeCCNU)耐药性的发展进行了研究。在每次体内传代时,用15mg/kg的MeCCNU处理这些克隆,导致肿瘤对该药物的反应迅速降低。这表明MeCCNU耐药性可能以适用于自发肿瘤及其转移灶的速率出现。克隆分离后不久,核型异质性就很明显,这对克隆的实验应用和转移疾病的特征具有潜在的重要意义。每次传代时对其中一个克隆进行核型分析表明,耐药性的发展与肿瘤细胞单个亚群的选择有关,但耐药性发展的动力学不能完全用这种简单的选择来解释。